Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients.

ABSTRACT:

Background

Bladder cancer (BlCa) heterogeneity and the lack of personalised prognosis lead to patients' highly variable treatment outcomes. Here, we have analysed the utility of the GAS5 tumour-suppressor lncRNA in improving BlCa prognosis.

Methods

GAS5 was quantified in a screening cohort of 176 patients. Hedegaard et al. (2016) (n = 476) and TCGA provisional (n = 413) were used as validation cohorts. Survival analysis was performed using recurrence and progression for NMIBC, or death for MIBC. Internal validation was performed by bootstrap analysis, and decision curve analysis was used to evaluate the clinical benefit on disease prognosis.

Results

GAS5 levels were significantly downregulated in BlCa and associated with invasive high-grade tumours, and high EORTC-ris

SUBMITTER: Avgeris M 

PROVIDER: S-EPMC6288135 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature